Genzyme Recalls Thyrogen Injection Vials Due to Glass Particulate Matter
Genzyme Corporation is recalling 27,022 vials of Thyrogen (thyrotropin alfa) because glass particles were found in the product after reconstitution.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, an FDA Class II recall involving a structural defect (glass particles) in an injectable drug is categorized as Severe (Score 4), particularly given the risk of injury from particulate matter in an intramuscular injection.
Plain-English summary
Genzyme Corporation is recalling 27,022 vials of Thyrogen (thyrotropin alfa for injection), 0.9 mg/mL, due to the presence of particulate matter. Specifically, glass particles were found in the product after reconstitution. The affected product is identified by Lot # E4029Y02 (carton) and E4029 (vial) with an expiration date of 09/2016.
The recalled product was distributed nationwide, as well as in Puerto Rico, Malaysia, Taiwan, Brazil, and Israel. Thyrogen is a prescription-only medication intended for intramuscular injection. Each carton contains four vials: two vials of Thyrogen and two vials of diluent.
Consumers and healthcare providers should stop using the affected vials immediately. Patients should contact their healthcare provider for further instructions or to obtain a replacement product. The recall is classified as FDA Class II, indicating a reasonable probability that use of the product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Thyrogen (thyrotropin alfa for injection), 0.9 mg/mL after reconstitution, For intramuscular injection only, Rx Only, Four vials per Carton, Carton contains 2 vials of Thyrogen and 2 vials of diluent, Storage: store at 2-8 C, Genzyme Corporation, Cambridge, MA 02142, NDC 58468-1
- Manufacturer
- Genzyme Corporation
- Category
- Drug — Injectable Prescription
- Affected units
- 27,022
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: E4029Y02 (carton)
- E4029 (vial) Exp 09/2016
Distribution
Part of a larger recall action
This product is one of 2 recalled by Genzyme Corporation under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Genzyme Corporation
See all →- LowGenzyme Recalls Clolar Injection Due to Missing Package Insert
FDA (Drugs) · 2017-11-22
- LowGenzyme Recalls Lumizyme Vials Due to Incorrect or Missing Lot and Expiration Dates
FDA (Drugs) · 2016-04-06
- SevereGenzyme Recalls Thyrogen Due to Glass Particles Found in Product
FDA (Drugs) · 2016-03-09
- HighGenzyme Recalls Seprafilm Adhesion Barrier Packs Due to Packaging Defect
FDA (Devices) · 2012-06-27
- HighGenzyme Recalls Seprafilm Adhesion Barrier Due to Packaging Sterility Risk
FDA (Devices) · 2012-06-27
Same hazard · particulate matter
See all →- SevereACTHAR Gel Recalled for Presence of Glass and Stopper Particulate Matter
FDA (Drugs) · 2026-09-02
- SevereB. Braun Recalls Lactated Ringer's Injection Due to Particulate Matter
FDA (Drugs) · 2026-09-02
- CriticalAmerican Regent Recalls Papaverine Hydrochloride Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Nitroglycerin Injection Due to Particulate Matter
FDA (Drugs) · 2026-08-26
- SevereAmerican Regent Recalls Cyanocobalamin Injections Due to Particulate Matter
FDA (Drugs) · 2026-08-26